Alembic Pharmaceuticals gets USFDA nod for Febuxostat Tablets

02 Jul 2019 Evaluate

Alembic Pharmaceuticals has received nod from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Febuxostat Tablets, 40 mg and 80 mg. The approved ANDA is therapeutically equivalent to the: reference listed drug (RLD), Uloric Tablets, 40 mg and 80 mg, of Takeda Pharmaceuticals U.S.A., Inc. (Takeda). Febuxostat Tablets has an estimated market size of $578 million for twelve months ending December 2018.

The company had previously received tentative approval for this ANDA. But now company has a total of 98 ANDA approvals (87 final approvals and 11 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.

Alembic Pharma Share Price

852.30 -4.95 (-0.58%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×